Ventricular fibrillation developed in a 19 year old woman taking the antihistamine astemizole. She was successfully resuscitated. QTc prolongation was found and persisted despite withdrawal of the drug. Aggravation of congenital long QTc syndrome by astemizole is postulated. More caution should be exercised with the use of this drug. (Br HeartJ' 1993;70:469-470) Astemizole is an antihistamine that is widely used to treat hay fever. series of electrocardiograms and during these it was noted that her QTc was persistently prolonged (table), though it did shorten with time. Astemizole has a long half-life (18-22 days), but even 2 months after the drug had been stopped the patient's QTc was still prolonged at 463 ms (upper limit of normal3 generally accepted to be 440 ms). Both her father's and sister's QTc intervals were prolonged initially. They were both taking the antihistamine terfenadine at the time and subsequent electrocardiograms taken in the drug-free state showed a QTc of 435 ms (the upper limit of normal) in the sister though QTc was still slightly prolonged in the father. There was no family history of syncope or sudden death and there were no hearing problems in any family member. Echocardiography, cardiac catherisation and electrophysiological investigation were carried out in the patient. The results of these tests were unremarkable. We concluded therefore that our patient and her father both had the long QT or Romano-Ward syndrome.
effects of histamine at the HI receptor site. It is one of several drugs of this type and is available without prescription. Over the past few years there have been several reports of serious ventricular arrhythmias in patients taking astemizole.1 All, however, have been the consequence of taking the drug in actual or suspected overdose. We report a case in which we postulate that astemizole contributed to the development of ventricular fibrillation in a young woman with what transpired to be congenital long QT syndrome.
series of electrocardiograms and during these it was noted that her QTc was persistently prolonged (table), though it did shorten with time. Astemizole has a long half-life (18-22 days), but even 2 months after the drug had been stopped the patient's QTc was still prolonged at 463 ms (upper limit of normal3 generally accepted to be 440 ms). Both her father's and sister's QTc intervals were prolonged initially. They were both taking the antihistamine terfenadine at the time and subsequent electrocardiograms taken in the drug-free state showed a QTc of 435 ms (the upper limit of normal) in the sister though QTc was still slightly prolonged in the father. There was no family history of syncope or sudden death and there were no hearing problems in any family member. Echocardiography, cardiac catherisation and electrophysiological investigation were carried out in the patient. The results of these tests were unremarkable. We concluded therefore that our patient and her father both had the long QT or Romano-Ward syndrome.
The patient was discharged on atenolol 50 mg twice daily and was well 6 months later. She takes beclomethasone intranasally for her hay fever and both she and her family have been warned not to take antihistamines. 
